Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
Omega Therapeutics (Nasdaq: OMGA), a biotech company developing programmable epigenomic mRNA medicines, has appointed Jennifer Nelson, Ph.D., as Senior Vice President of Research. Dr. Nelson brings over 20 years of experience in RNA- and DNA-based therapies and platform development. She previously served as Vice President of Research at Flagship Pioneering and held key positions at Laronde and Moderna Therapeutics.
The company's CEO, Mahesh Karande, expressed confidence in Dr. Nelson's expertise to advance the OMEGA platform and pursue strategic partnerships. Dr. Nelson's appointment comes as Thomas McCauley, Ph.D., the former Chief Scientific Officer, leaves the company. Omega Therapeutics is focused on developing programmable epigenomic mRNA medicines to treat various diseases, including cancer and obesity.
Omega Therapeutics (Nasdaq: OMGA), una compagnia biotech che sviluppa medicinali mRNA epigenomici programmabili, ha nominato Jennifer Nelson, Ph.D., come Vicepresidente Senior della Ricerca. La Dr.ssa Nelson porta con sé oltre 20 anni di esperienza nelle terapie basate su RNA e DNA e nello sviluppo di piattaforme. In precedenza, ha ricoperto il ruolo di Vicepresidente della Ricerca presso Flagship Pioneering e ha occupato posizioni chiave presso Laronde e Moderna Therapeutics.
Il CEO della compagnia, Mahesh Karande, ha espresso fiducia nell'esperienza della Dr.ssa Nelson per far progredire la piattaforma OMEGA e perseguire alleanze strategiche. La nomina della Dr.ssa Nelson avviene mentre Thomas McCauley, Ph.D., l'ex Chief Scientific Officer, lascia l'azienda. Omega Therapeutics è focalizzata sullo sviluppo di medicinali mRNA epigenomici programmabili per trattare diverse malattie, tra cui cancro e obesità.
Omega Therapeutics (Nasdaq: OMGA), una empresa biotecnológica que desarrolla medicamentos de ARN mensajero epigenómicos programables, ha nombrado a Jennifer Nelson, Ph.D., como Vicepresidenta Senior de Investigación. La Dra. Nelson aporta más de 20 años de experiencia en terapias basadas en ARN y ADN y en el desarrollo de plataformas. Anteriormente, se desempeñó como Vicepresidenta de Investigación en Flagship Pioneering y ocupó puestos clave en Laronde y Moderna Therapeutics.
El CEO de la empresa, Mahesh Karande, expresó confianza en la capacidad de la Dra. Nelson para avanzar en la plataforma OMEGA y buscar asociaciones estratégicas. El nombramiento de la Dra. Nelson se da mientras Thomas McCauley, Ph.D., el ex Director Científico, deja la empresa. Omega Therapeutics se centra en desarrollar medicamentos de ARN mensajero epigenómicos programables para tratar diversas enfermedades, incluida la cáncer y la obesidad.
오메가 테라퓨틱스(Nasdaq: OMGA)는 프로그래머블 에피게노믹 mRNA 의약품을 개발하는 생명공학 회사로, 제니퍼 넬슨 박사를 연구 부사장으로 임명했습니다. 넬슨 박사는 RNA 및 DNA 기반 치료 및 플랫폼 개발 분야에서 20년 이상의 경험을 가지고 있습니다. 그녀는 이전에 플래그십 파이오니어링의 연구 부사장으로 재직했으며, 라론드와 모더나 테라퓨틱스에서 중요한 직책을 맡았습니다.
회사의 CEO인 마헤시 칼란데는 넬슨 박사의 전문성을 바탕으로 OMEGA 플랫폼을 발전시키고 전략적 파트너십을 추구할 것이라고 믿음을 표명했습니다. 넬슨 박사의 임명은 전 최고 과학 책임자인 토마스 맥컬리 박사가 회사를 떠나는 시점에 이루어졌습니다. 오메가 테라퓨틱스는 다양한 질환, 특히 암과 비만을 치료하기 위해 프로그래머블 에피게노믹 mRNA 의약품 개발에 집중하고 있습니다.
Omega Therapeutics (Nasdaq: OMGA), une entreprise biopharmaceutique développant des médicaments mRNA épigénomiques programmables, a nommé Jennifer Nelson, Ph.D., au poste de Vice-Présidente Senior de la Recherche. Dr. Nelson apporte plus de 20 ans d'expérience dans les thérapies basées sur l'ARN et l'ADN ainsi que dans le développement de plateformes. Elle a précédemment été Vice-Présidente de la Recherche chez Flagship Pioneering et a occupé des postes clés chez Laronde et Moderna Therapeutics.
Le PDG de l'entreprise, Mahesh Karande, a exprimé sa confiance dans l'expertise de Dr. Nelson pour faire progresser la plateforme OMEGA et poursuivre des partenariats stratégiques. La nomination de Dr. Nelson intervient alors que Thomas McCauley, Ph.D., l'ancien directeur scientifique, quitte l'entreprise. Omega Therapeutics se concentre sur le développement de médicaments mRNA épigénomiques programmables pour traiter diverses maladies, notamment le cancer et l'obésité.
Omega Therapeutics (Nasdaq: OMGA), ein Biotech-Unternehmen, das programmierbare epigenomische mRNA-Medikamente entwickelt, hat Jennifer Nelson, Ph.D., zur Senior Vice President of Research ernannt. Dr. Nelson bringt über 20 Jahre Erfahrung in RNA- und DNA-basierten Therapien sowie in der Plattformentwicklung mit. Zuvor war sie Vice President of Research bei Flagship Pioneering und hatte Schlüsselpositionen bei Laronde und Moderna Therapeutics inne.
Der CEO des Unternehmens, Mahesh Karande, äußerte Vertrauen in Dr. Nelsons Fachwissen, um die OMEGA-Plattform voranzubringen und strategische Partnerschaften zu verfolgen. Dr. Nelsons Ernennung erfolgt, während Thomas McCauley, Ph.D., der ehemalige Chief Scientific Officer, das Unternehmen verlässt. Omega Therapeutics konzentriert sich auf die Entwicklung programmierbarer epigenomischer mRNA-Medikamente zur Behandlung verschiedener Krankheiten, einschließlich Krebs und Fettleibigkeit.
- Appointment of Jennifer Nelson, Ph.D., as Senior Vice President of Research, bringing 20+ years of experience in RNA- and DNA-based therapies
- Dr. Nelson's expertise expected to advance the OMEGA platform and pursue strategic partnerships
- Clinical proof of platform achieved, demonstrating progress in precision epigenomic control
- Departure of Thomas McCauley, Ph.D., the former Chief Scientific Officer
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the addition of Jennifer Nelson, Ph.D., to the Company’s executive leadership team in the role of Senior Vice President of Research. She brings over 20 years of experience working with RNA- and DNA-based therapies and technologies, and extensive expertise as a leader in building novel platforms.
“Jennifer has an impressive background as a scientist, platform strategist and biopharma leader, with a successful track record of fostering innovation in the field of RNA biology,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. “As we continue to advance the OMEGA platform and pursue high-value strategic partnerships for our programmable epigenomic mRNA therapeutics, we believe her expertise across bio-platform development and her passion for the advancement of mRNA-based therapeutics will be invaluable to our team. I’m delighted to welcome Jennifer and I look forward to partnering with her.”
Dr. Nelson added, “Omega’s epigenomic controllers have significant potential to address a broad range of diseases, from cancer to obesity. The clinical proof of platform achieved to date underscores the progress the management team has made to advance precision epigenomic control. I am thrilled to build on this success and help realize the full potential of this approach to bring a new class of programmable mRNA medicines to patients.”
Prior to joining Omega, Dr. Nelson served as Vice President of Research at Flagship Pioneering, where she helped launch and develop bio-platform companies, including oversight of platform-related strategy and research. Previously, she served as Head of Vaccines at Laronde, having formerly led Platform Research, and played pivotal roles throughout her tenure advancing the company’s preclinical development, manufacturing capabilities and portfolio and IP strategy. Earlier in her career, Dr. Nelson held management positions of increasing responsibility at Moderna Therapeutics, culminating in a leading role advancing novel approaches to leveraging mRNA for therapeutic purposes. Dr. Nelson began her industry career at Archemix Therapeutics and later worked at GSK prior to joining Moderna.
Dr. Nelson is an author on numerous articles and patents focused on various nucleic acid technologies, including mRNA, circular RNA, ribozymes and aptamers. She received a Ph.D. in Chemistry and Biochemistry from the University of Colorado Boulder, a Master of Liberal Arts in Extension Studies, field: Management from Harvard University, and a B.A. from Northwestern University.
Thomas McCauley, Ph.D., who served as Chief Scientific Officer since 2019, will leave the company to pursue a new opportunity. “On behalf of the entire team, I would like to express our sincere appreciation for Tom’s contributions and service to Omega,” said Mr. Karande. “Tom was a great partner in helping to shape and advance our pioneering science and novel platform technology and we wish him well with his future endeavors.”
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions.
For more information, visit omegatherapeutics.com, or follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements surrounding the potential of our development candidates; potential strategic partnerships; and Dr. Nelson’s impact on the Company in furthering its business objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controllers due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; volatility in capital markets and general economic conditions; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; potential delays in and unforeseen costs arising from our clinical trials; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; difficulties manufacturing the novel technology on which our epigenomic controller candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
FAQ
Who is the new Senior Vice President of Research at Omega Therapeutics (OMGA)?
What is Omega Therapeutics' (OMGA) main focus in biotechnology?
What is the OMEGA platform developed by Omega Therapeutics (OMGA)?
Who is leaving Omega Therapeutics (OMGA) as announced in the press release?
